Database

Contera Pharma

Solution provided
Technology
Supplier identity
General description

Contera Pharma identifies and develops innovative treatments for patients suffering from movement disorders. We use our expertise in drug discovery and development in close collaboration with expert individuals and organizations to provide foundations for success.


The lead project JM-010 is approved for Phase IIa clinical trials for treatment of dyskinesia associated with Parkinson's disease.

Type of Supplier
Biotechnology Company - Therapeutics
Sector of activity
  • Drug Discovery / Research & Development
Region
Denmark, DK
Regional access broker
  • Niels Westergaard, Biopeople
  • Sophie Labrosse, Biopeople
Activity description
Know-how, expertise available

Technology

Contera Pharma has developed new strategies to identify drug development projects characterized by high probability of success, fast access to clinical development and long exclusivity.

Indications

Movement disorders are a group of diseases that affect the ability to produce and control body movement, and are often associated with neurological disorders or conditions associated with neurological dysfunction. One example of a movement disorder is dyskinesia which characterized by various involuntary movements, which can affect discrete body parts or can become generalized and severely disabling.

Projects

Contera Pharma develops new innovative treatments of movement disorders. The lead project JM-010 is approved to start Phase IIa studies for treatment of L-DOPA induced dyskinesia. Contera Pharma explores preclinical projects in other movement disorders like tardive dyskinesia.

Training and Staff possibilities
No
Contact information
Name
Mikael
Surname
Thomsen
Function
CSO
Address
Kvæsthusgade 5C, 4.
1251  Copenhagen K
Denmark